Navigation Links
2008 a Record Year for Gerresheimer
Date:4/29/2009

DUSSELDORF, Germany, April 29 /PRNewswire-FirstCall/ --

- Strong Focus on the Markets of Pharma & Life Science

- Annual General Meeting Passes Dividend of EUR0.40 per Share

The Annual General Meeting of Gerresheimer AG today passed an unchanged dividend of EUR0.40 per share following the record year in 2008.

The Company finished the financial year 2008 with record results. Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and operating results (adjusted EBITDA) of EUR206.4m (prior year EUR181.6m).

At the Annual General Meeting in Dusseldorf the CEO Dr. Axel Herberg summarized the highlights of the financial year 2008: "We have achieved record levels in terms of sales and earnings. Gerresheimer is on a good course and will show itself to be very robust even in times of crisis."

The shareholders approved the actions of the members of the Company's Supervisory Board and Management Board for the financial year 2008 and, as in the prior year, passed a dividend payment of EUR0.40 per share.

With share capital representation of 59.44% the Annual General Meeting passed the following resolutions:

ITEM 2: Appropriation of net earnings for the financial year 2008:

(99.99% of votes in favor)

ITEM 3: Approval of the actions of the Management Board members for the financial year 2008:

(100% of votes in favor)

ITEM 4: Approval of the actions of the Supervisory Board members for the financial year 2008:

(100% of votes in favor)

ITEM 5: Supplementary election to the Supervisory Board of Mr. Theodor Stuth, Auditor and Certified Tax Advisor, Neuss:

    (100% of votes in favor)
    ITEM 6: Election of the auditor for the financial year 2009:
    (99.99% of votes in favor)
    The speech is available onhttp://www.gerresheimer.com/en/press.html.
    About Gerresheimer

Gerresheimer employs around 10,000 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharma­ceu­tical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.(WKN: 587300)

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Globus Medical Announces Record 2nd Quarter 2007 Results
2. BioSpace Draws Record Crowd to Chicago Life Science Career Fair
3. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
4. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
5. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. China Biologic Products Reports Record Third Quarter 2007 Results
8. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
9. The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
10. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
(Date:4/26/2017)... Va. (PRWEB) , ... April 26, 2017 , ... ... make headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding ... Environment – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by ...
(Date:4/25/2017)... ... April 25, 2017 , ... L3 Clinical Trials, the ... company is now a certified iMedNet eClinical and Electronic Data Capture software designer ... clinical research team to build, customize and manage clinical trial data capture and ...
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum Review IRB and ... multiple sessions at this week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting ... clinical research. , "We are excited to present subject matter expertise on topics that ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):